GlassScriptPhysician profile
John D Wysocki
NPI 1457594103
$11,618.80
in general payments reported to CMS, 2019-2025
41 companies · $2,466 in 2025
The $2,466 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,987 · 2020: $512 · 2021: $661 · 2022: $1,023 · 2023: $1,663 · 2024: $3,306 · 2025: $2,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,508 · Consulting Fee: $900 · Education: $27.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,508.26 |
| Consulting Fee | $900.00 |
| Education | $27.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,644.34 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,820.88 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $945.39 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Iterative Scopes, INC. | $900.00 | 2024 | Skout |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $844.69 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $606.73 | 2021-2024 | Zeposia |
| Pfizer INC. | $373.97 | 2019-2025 | |
| Ardelyx, INC. | $288.34 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $238.66 | 2024-2025 | Omvoh, Zepbound, Mounjaro |
| Madrigal Pharmaceuticals | $146.67 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $129.81 | 2019-2021 | |
| Ucb, INC. | $128.91 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $125.28 | 2019 | |
| Ironwood Pharmaceuticals, INC | $116.65 | 2023-2024 | Linzess |
| Genzyme Corporation | $116.35 | 2023-2025 |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wysocki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.